Dianne L Newton
Overview
Explore the profile of Dianne L Newton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang W, DeRyckere D, Hunter D, Liu J, Stashko M, Minson K, et al.
J Med Chem
. 2014 Jul;
57(16):7031-41.
PMID: 25068800
We previously reported a potent small molecule Mer tyrosine kinase inhibitor UNC1062. However, its poor PK properties prevented further assessment in vivo. We report here the sequential modification of UNC1062...
2.
Hollingshead M, Stockwin L, Alcoser S, Newton D, Orsburn B, Bonomi C, et al.
BMC Genomics
. 2014 Jun;
15:393.
PMID: 24885658
Background: Development of cancer therapeutics partially depends upon selection of appropriate animal models. Therefore, improvements to model selection are beneficial. Results: Forty-nine human tumor xenografts at in vivo passages 1,...
3.
Morrison B, Mullendore M, Stockwin L, Borgel S, Hollingshead M, Newton D
Cancer Med
. 2014 Jan;
2(5):687-700.
PMID: 24403234
Oxyphenisatin (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one) and several structurally related molecules have been shown to have in vitro and in vivo antiproliferative activity. This study aims to confirm and extend mechanistic studies by focusing...
4.
Ye X, Chan K, Prieto D, Luke B, Johann Jr D, Stockwin L, et al.
Methods Mol Biol
. 2013 Apr;
1002:133-49.
PMID: 23625401
Differential (18)O/(16)O stable isotopic labeling that relies on post-digestion (18)O exchange is a simple and efficient method for the relative quantitation of proteins in complex mixtures. This method incorporates two...
5.
Saini V, Hose C, Monks A, Nagashima K, Han B, Newton D, et al.
PLoS One
. 2012 Aug;
7(8):e41401.
PMID: 22870217
Recently, there has been renewed interest in the role of tumor stem cells (TSCs) in tumorigenesis, chemoresistance, and relapse of malignant tumors including osteosarcoma. The potential exists to improve osteosarcoma...
6.
Glaros T, Stockwin L, Mullendore M, Smith B, Morrison B, Newton D
Cancer Chemother Pharmacol
. 2012 Apr;
70(1):207-12.
PMID: 22526412
Purpose: To establish whether NSC80467, a novel fused naphthquinone imidazolium, has a similar spectrum of activity to the well-characterized "survivin suppressant" YM155 and to extend mechanistic studies for this structural...
7.
Orsburn B, Stockwin L, Newton D
Expert Rev Proteomics
. 2011 Aug;
8(4):483-94.
PMID: 21819303
The response to extracellular stimuli often alters the phosphorylation state of plasma membrane- associated proteins. In this regard, generation of a comprehensive membrane phosphoproteome can significantly enhance signal transduction and...
8.
Hancock C, Stockwin L, Han B, Divelbiss R, Jun J, V Malhotra S, et al.
Free Radic Biol Med
. 2010 Oct;
50(1):110-21.
PMID: 20971185
In this study, a Cu(2+) chelate of the novel thiosemicarbazone NSC 689534 was evaluated for in vitro and in vivo anti-cancer activity. Results demonstrated that NSC 689534 activity (low micromolar...
9.
Stockwin L, Yu S, Borgel S, Hancock C, Wolfe T, Phillips L, et al.
Int J Cancer
. 2010 Jun;
127(11):2510-9.
PMID: 20533281
The "Warburg effect," also termed aerobic glycolysis, describes the increased reliance of cancer cells on glycolysis for ATP production, even in the presence of oxygen. Consequently, there is continued interest...
10.
Han B, Stockwin L, Hancock C, Yu S, Hollingshead M, Newton D
J Proteome Res
. 2010 Jun;
9(8):4016-27.
PMID: 20515076
The indenoisoquinoline NSC724998 is a novel topoisomerase I (Top1) inhibitor entering Phase I clinical trials at the National Cancer Institute, USA. In this study, 2-D PAGE analysis was performed on...